A Trial to Assess the Safety Immunogenicity and Efficacy of a Trivalent Rotavirus P2-VP8 Subunit Vaccine in Prevention of Severe Rotavirus Gastroenteritis in Healthy Infants in Africa and India

  • STATUS
    Recruiting
  • End date
    Dec 15, 2025
  • participants needed
    8200
  • sponsor
    PATH
Updated on 15 April 2021

Summary

The trial will be a multinational, randomized, double-blind, double-dummy, endpoint driven, group-sequential, active comparator-controlled study, in which participating infants will be randomized 1:1 to receive either: 1) 90 g of the TV P2-VP8 vaccine IM plus oral placebo, or 2) Rotarix per os (PO) plus IM placebo. Participants will receive three doses of TV P2-VP8/placebo IM and two doses of Rotarix/placebo PO at monthly intervals starting at 6 to <8 weeks of age, administered concomitantly with EPI/UIP vaccines. To maintain the blind, infants allocated to the TV P2-VP8 vaccine arm will receive both TV P2-VP8 IM as well as oral placebo vaccine, and infants allocated to receive Rotarix will receive both Rotarix PO and placebo IM. Active surveillance for episodes of gastroenteritis (GE) will be conducted throughout the study, through weekly contact with participants' parents. Unsolicited AEs grade 2 through 28 days after the last study vaccination will be recorded in the study database, as will data for SAEs (including intussusception) throughout the study.

Details
Condition Rotavirus Infection of Children
Treatment Rotarix, TV P2-VP8
Clinical Study IdentifierNCT04010448
SponsorPATH
Last Modified on15 April 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Healthy infants as established by medical history and clinical examination before entering the study
Age: 6 and <8 weeks at the time of first study vaccination (42 days through 55 days old, inclusive, with the day after birth considered 1-day old)
Parental/legal guardian's ability and willingness to provide written informed consent
Intention of the participants' parents to remain in the area with the child during the study period

Exclusion Criteria

Acute disease at the time of first study vaccination - temporary exclusion
Presence of fever on the day of first study vaccination (axillary temperature >37.6oC)
temporary exclusion
Concurrent participation in another clinical trial throughout the entire timeframe for this study (participation in non-interventional observational study is allowed if there is no blood draw)
Presence of severe malnutrition (weight-for-height z-score -3SD median, per WHO published child growth standards) or any systemic disorder (cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrine, immunological, dermatological, neurological, cancer or autoimmune disease) as determined by medical history and/or physical examination that would compromise the participant's health or is likely to result in nonconformance to the protocol
History of premature birth (<37 weeks gestation) and/or birth weight of <2.5 kg
History of congenital abdominal disorders, intussusception, or abdominal surgery
Prior receipt of rotavirus vaccine
Known sensitivity or allergy to any components of the study vaccine
Contraindication to any EPI/UIP vaccine
History of anaphylactic reaction
Major congenital or genetic defect
Parents not able, available or willing to accept active weekly follow-up by the study staff
Receipt of any immunoglobulin therapy and/or blood products
Nursing infants whose mother are receiving immunosuppressive biologicals
History of chronic administration (defined as more than 14 days) of immunosuppressant medications, including corticosteroids (those on inhaled or topical steroids may be permitted to participate in the study)
Any medical condition in the participant or parents that, in the judgment of the investigator, would interfere with or serves as a contraindication to protocol adherence or a parents' ability to give informed consent
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note